Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway

Shu Wakino, Koichi Hayashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although PPARgamma ligands have an antihypertensive effect in vivo, the precise mechanism has not been fully elucidated. We examined their effects on Rho/Rho kinase pathway, a key regulator of vascular tone. In cultured rat aortic smooth muscle cells, Rho kinase activated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone. The roles of Vav, a GTP/GDP exchange factor upregulating Rho kinase activity, and SHP-2, protein tyrosine phosphatase that dephosphorylated Vav and subsequently inactivated Rho kinase were examined. Both pioglitazone and troglitazone upregulated SHP-2, particularly in the cytosolic fraction, and the SHP-2-bound Vav, and reduced the phosphorylation of Vav. These mechanisms may contribute to the hemodynamic, in addition to metabolic, action by PPARgamma ligands in hypertensive, metabolic syndrome.

Original languageEnglish
Pages (from-to)693-699
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Volume63
Issue number4
Publication statusPublished - 2005

Fingerprint

rho-Associated Kinases
PPAR gamma
pioglitazone
troglitazone
Antihypertensive Agents
Ligands
Non-Receptor Type 11 Protein Tyrosine Phosphatase
Guanine Nucleotide Exchange Factors
Guanosine Triphosphate
Angiotensin II
Smooth Muscle Myocytes
Blood Vessels
Hemodynamics
Phosphorylation

Cite this

Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway. / Wakino, Shu; Hayashi, Koichi.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 63, No. 4, 2005, p. 693-699.

Research output: Contribution to journalArticle

@article{18c00750013046659b16f135dac49984,
title = "Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway",
abstract = "Although PPARgamma ligands have an antihypertensive effect in vivo, the precise mechanism has not been fully elucidated. We examined their effects on Rho/Rho kinase pathway, a key regulator of vascular tone. In cultured rat aortic smooth muscle cells, Rho kinase activated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone. The roles of Vav, a GTP/GDP exchange factor upregulating Rho kinase activity, and SHP-2, protein tyrosine phosphatase that dephosphorylated Vav and subsequently inactivated Rho kinase were examined. Both pioglitazone and troglitazone upregulated SHP-2, particularly in the cytosolic fraction, and the SHP-2-bound Vav, and reduced the phosphorylation of Vav. These mechanisms may contribute to the hemodynamic, in addition to metabolic, action by PPARgamma ligands in hypertensive, metabolic syndrome.",
author = "Shu Wakino and Koichi Hayashi",
year = "2005",
language = "English",
volume = "63",
pages = "693--699",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "4",

}

TY - JOUR

T1 - Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway

AU - Wakino, Shu

AU - Hayashi, Koichi

PY - 2005

Y1 - 2005

N2 - Although PPARgamma ligands have an antihypertensive effect in vivo, the precise mechanism has not been fully elucidated. We examined their effects on Rho/Rho kinase pathway, a key regulator of vascular tone. In cultured rat aortic smooth muscle cells, Rho kinase activated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone. The roles of Vav, a GTP/GDP exchange factor upregulating Rho kinase activity, and SHP-2, protein tyrosine phosphatase that dephosphorylated Vav and subsequently inactivated Rho kinase were examined. Both pioglitazone and troglitazone upregulated SHP-2, particularly in the cytosolic fraction, and the SHP-2-bound Vav, and reduced the phosphorylation of Vav. These mechanisms may contribute to the hemodynamic, in addition to metabolic, action by PPARgamma ligands in hypertensive, metabolic syndrome.

AB - Although PPARgamma ligands have an antihypertensive effect in vivo, the precise mechanism has not been fully elucidated. We examined their effects on Rho/Rho kinase pathway, a key regulator of vascular tone. In cultured rat aortic smooth muscle cells, Rho kinase activated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone. The roles of Vav, a GTP/GDP exchange factor upregulating Rho kinase activity, and SHP-2, protein tyrosine phosphatase that dephosphorylated Vav and subsequently inactivated Rho kinase were examined. Both pioglitazone and troglitazone upregulated SHP-2, particularly in the cytosolic fraction, and the SHP-2-bound Vav, and reduced the phosphorylation of Vav. These mechanisms may contribute to the hemodynamic, in addition to metabolic, action by PPARgamma ligands in hypertensive, metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=18944364077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18944364077&partnerID=8YFLogxK

M3 - Article

C2 - 15828239

AN - SCOPUS:18944364077

VL - 63

SP - 693

EP - 699

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 4

ER -